Type 2 diabetes mellitus treatment patterns and Healthcare costs in the elderly population

被引:5
|
作者
Erwin, Gary
Iyer, Shrividya
Rajagopalan, Rukmini
Astuto, James
Wilson, Patricia
Schaneman, Justin
Kleinman, Nathan
机构
[1] Omnicare Inc, Covington, KY USA
[2] Takeda Pharmaceut N Amer Inc, Med & Sci Affairs, Outcomes Res, Lincolnshire, IL USA
[3] Verizon Commun, Alpharetta, GA USA
[4] Associates & Wilson, Rosemont, PA USA
[5] Opt & Choices Inc, Cheyenne, WY USA
[6] HCMS Grp, Cheyenne, WY USA
关键词
D O I
10.2165/00115677-200614020-00002
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objective: The main objective of this study was to evaluate treatment patterns and to assess the relationship between diabetes mellitus-related vascular complications and the total medical/prescription drug costs in the elderly population using a large, national, self-insured employer database. Methods: Type 2 diabetes patients who were >= 65 years of age were identified from a large, national, self-insured employer database. The study population included 9959 type 2 diabetes patients with an index date ranging from 1996 to 2001. Patients were enrolled for a minimum of 12 months, and so the enrollment period spanned the years 1996 to 2002. The date of the patients' type 2 diabetes diagnosis was used as the index date for each patient. Vascular complications (cardiovascular, cerebrovascular, microvascular, and peripheral vascular) were grouped separately into a cohort hierarchy for analysis. The total annual healthcare costs (i.e. all claim costs, including prescription costs) were estimated for each group with adjustment for age, sex, and the severity of the complication. The hospitalization status was used as a measure of severity. Costs were also estimated for specific diabetes-related complications. All costs were reported in 2002 US dollars. Results: The adjusted total annual costs for patients without hospitalizations ranged from $US4877 with no complications to $US12 271 with four complications. For patients with hospitalizations, the adjusted total annual costs ranged from $US18 839 with one complication to $US41 011 with four complications. The average annual costs per patient without/with hospitalizations for each vascular category were: cardiovascular, $US8664/$US23 224; cerebrovascular, $US10 352/$US24 279; microvascular, $US10 271/$US33 696; and peripheral vascular. $US10 925/$US28 369. The average annual costs per patient without/with hospitalizations for specific conditions were: hypertension, $US7642/$US17 978; stroke, $US15 349/$US25 333; end-stage renal disease, $US23 657/$US63 173; and lower limb amputation, $US53 286/$US52 434. Conclusion: Type 2 diabetes complications in the elderly population create significant healthcare expenditure for employers, their beneficiaries. and third-party payors. Preventive strategies and better management of type 2 diabetes in elderly patients could reduce the occurrence of such complications and have remarkable cost-saving implications.
引用
收藏
页码:75 / 83
页数:9
相关论文
共 50 条
  • [31] Treatment of Diabetes mellitus Type 2
    Matthaei, S.
    Bierwirth, R.
    Fritsche, A.
    Gallwitz, B.
    Haering, H. -U.
    Joost, H. -G.
    Kellerer, M.
    Kloos, C.
    Kunt, T.
    Nauck, M.
    Schernthaner, G.
    Siegel, E.
    Thienel, F.
    DIABETOLOGIE UND STOFFWECHSEL, 2011, 6 : S131 - S136
  • [32] Treatment of diabetes mellitus type 2
    Matthaei, S.
    Haering, H. U.
    DIABETOLOGIE UND STOFFWECHSEL, 2007, 2 : S173 - S177
  • [33] Treatment of type 2 diabetes mellitus
    Florence, JA
    Yeager, BF
    AMERICAN FAMILY PHYSICIAN, 1999, 59 (10) : 2835 - 2844
  • [34] Treatment of Diabetes mellitus Type 2
    Matthaei, S.
    Bierwirth, R.
    Fritsche, A.
    Gallwitz, B.
    Haering, H. -U.
    Joost, H. -G.
    Kellerer, M.
    Kloos, C.
    Kunt, T.
    Nauck, M.
    Schernthaner, G.
    Siegel, E.
    Thienel, F.
    DIABETOLOGIE UND STOFFWECHSEL, 2012, 7 : S124 - S129
  • [35] Treatment of type 2 diabetes mellitus
    Feinglos, MN
    Bethel, MA
    MEDICAL CLINICS OF NORTH AMERICA, 1998, 82 (04) : 757 - +
  • [36] Treatment of the Diabetes Mellitus Type 2
    Matthaei, S.
    Bierwirth, R.
    Fritsche, A.
    Gallwitz, B.
    Haering, H.-U.
    Joost, H. -G
    Kellerer, M.
    Kloos, C.
    Kunt, T.
    Nauck, M.
    Schernthaner, G.
    Siegel, E.
    Thienel, F.
    DIABETOLOGIE UND STOFFWECHSEL, 2009, 4 : S138 - S143
  • [37] DIRECT MEDICAL COST AND HEALTHCARE RESOURCE UTILIZATION IN ELDERLY PATIENTS WITH TYPE 2 DIABETES MELLITUS AMONG INSURED URBAN POPULATION IN CHINA
    Liu, Q.
    Chen, Y.
    Chu, Y.
    VALUE IN HEALTH, 2016, 19 (07) : A670 - A670
  • [38] The burden of hypoglycemia on healthcare utilization, costs, and quality of life among type 2 diabetes mellitus patients
    Williams, Setareh A.
    Shi, Lizheng
    Brenneman, Susan K.
    Johnson, Jonathan C.
    Wegner, Jessica C.
    Fonseca, Vivian
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2012, 26 (05) : 399 - 406
  • [39] Treatment of Diabetes mellitus Type 2
    Matthaei, S.
    Bierwirth, R.
    Fritsche, A.
    Gallwitz, B.
    Haering, H. -U.
    Joost, H. -G.
    Kellerer, M.
    Kloos, C.
    Kunt, T.
    Nauck, M.
    Schernthaner, G.
    Siegel, E.
    Thienel, F.
    DIABETOLOGIE UND STOFFWECHSEL, 2010, 5 : S127 - S132
  • [40] Treatment of diabetes mellitus type 2
    Matthaei, S.
    Haering, H. U.
    DIABETOLOGIE UND STOFFWECHSEL, 2008, 3 : S157 - S161